ea0063oc3.1 | Cushing's and acromegaly | ECE2019
Pivonello Rosario
, Fleseriu Maria
, Newell-Price John
, Bertagna Xavier
, Findling James
, Shimatsu Akira
, Gu Feng
, Auchus Richard
, Leelawattana Rattana
, Jig Lee Eun
, Hee Kim Jung
, Lacroix Andre
, Laplanche Audrey
, O'Connell Paul
, M Pedroncelli Alberto
, Tauchmanova Libuse
, MK Biller Beverly
Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...